PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month Low on Insider Selling

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) hit a new 52-week low on Thursday after an insider sold shares in the company. The company traded as low as $58.37 and last traded at $58.2550, with a volume of 547,250 shares trading hands. The stock had previously closed at $60.23.

Specifically, VP Mark Boulding sold 2,812 shares of the company’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $61.88, for a total value of $174,006.56. Following the transaction, the vice president directly owned 105,272 shares in the company, valued at $6,514,231.36. The trade was a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Raymond James Financial set a $106.00 target price on shares of PTC Therapeutics in a report on Tuesday, October 20th. Wall Street Zen downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. Truist Financial began coverage on shares of PTC Therapeutics in a research note on Friday, October 16th. They issued a “hold” rating and a $62.00 price target for the company. Cantor Fitzgerald raised their target price on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Finally, Leerink Partners began coverage on PTC Therapeutics in a research note on Monday, September 14th. They set an “outperform” rating and a $98.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.23.

Check Out Our Latest Research Report on PTCT

PTC Therapeutics Stock Performance

The stock has a market cap of $4.87 billion, a P/E ratio of -41.61, a price-to-earnings-growth ratio of 4.43 and a beta of 0.52. The firm’s 50 day moving average is $63.64 and its 200 day moving average is $70.04.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.76). The business had revenue of $357.81 million for the quarter, compared to the consensus estimate of $306.43 million. The business’s revenue was up 69.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. As a group, analysts expect that PTC Therapeutics, Inc. will post 0.49 EPS for the current fiscal year.

PTC Therapeutics announced that its Board of Directors has initiated a share repurchase program on Tuesday, November 3rd that allows the company to repurchase $500 million in shares. This buyback authorization allows the biopharmaceutical company to purchase up to 9.8% of its stock through open market purchases. Share buyback programs are often a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in PTC Therapeutics in the 2nd quarter valued at $1,139,089,000. Jupiter Topco LLC acquired a new stake in PTC Therapeutics during the second quarter valued at approximately $590,182,000. Janus Henderson Group PLC boosted its holdings in PTC Therapeutics by 48.3% in the first quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock worth $489,997,000 after purchasing an additional 2,342,101 shares during the period. William Blair Investment Management LLC bought a new position in shares of PTC Therapeutics during the second quarter valued at approximately $140,520,000. Finally, Bank of America Corp DE acquired a new position in shares of PTC Therapeutics during the second quarter valued at $118,462,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Further Reading

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.